COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
Demographic Details | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Male | 450 (67.7) | 745 (64.2) | 0.13 |
Indigenous | 46 (6.9) | 74 (6.4) | 0.87 |
Non-Indigenous | 404 (60.8) | 671 (57.8) | |
Female | 215 (32.3) | 416 (35.8) | 0.13 |
Indigenous | 59 (8.9) | 90 (7.8) | 0.10 |
Non-Indigenous | 156 (23.5) | 326 (28.1) |
Category of Admission | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Drug | 19 (17.1) | 16 (8.8) | 0.06 |
Male | 2 (4.3) | 9 (11.0) | 0.20 |
Female | 17 (26.6) | 7 (7.1) | <0.01 |
Infection | 19 (17.1) | 40 (22.1) | 0.29 |
Male | 6 (12.8) | 22 (26.8) | <0.05 |
Female | 13 (20.3) | 18 (18.2) | 0.84 |
Local wound infection | 6 (5.4) | 19 (10.5) | 0.13 |
Male | 1 (2.1) | 9 (11.0) | 0.09 |
Female | 5 (7.8) | 10 (10.1) | 0.78 |
Gastrointestinal | 16 (14.4) | 16 (8.8) | 0.18 |
Male | 9 (19.1) | 7 (8.5) | 0.17 |
Female | 7 (10.9) | 9 (9.1) | 0.79 |
Trauma | 24 (21.6) | 43 (23.8) | 0.56 |
Male | 6 (12.8) | 4 (4.9) | 0.18 |
Female | 18 (28.1) | 39 (39.4) | 0.12 |
Alcohol | 4 (3.6) | 12 (6.6) | 0.30 |
Male | 4 (8.5) | 6 (7.3) | 1.0 |
Female | 0 (0.0) | 6 (6.1) | 0.08 |
Others | 23 (20.7) | 35 (19.3) | 0.99 |
Male | 19 (40.4) | 25 (30.5) | 0.44 |
Female | 4 (6.3) | 10 (10.1) | 0.57 |
Admission Category | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Drug | 48 (8.1) | 135 (12.9) | <0.01 |
Male | 27 (6.3) | 87 (12.3) | <0.01 |
Female | 21 (12.5) | 48 (14.1) | 0.78 |
Infection * | 83 (13.9) | 117 (11.1) * | 0.08 |
Male | 56 (13.1) | 67 (9.4) † | 0.06 |
Female | 27 (16.1) | 50 (14.7) ‡ | 0.60 |
Wound infection | 29 (4.9) | 61 (5.8) | 0.50 |
Male | 20 (4.7) | 46 (6.5) | 0.24 |
Female | 9 (5.4) | 15 (4.4) | 0.66 |
Gastrointestinal | 58 (9.7) | 80 (7.6) | 0.14 |
Male | 49 (11.5) | 46 (6.5) | <0.01 |
Female | 9 (5.4) | 34 (10.0) | 0.12 |
Trauma | 54 (9.1) | 86 (8.2) | 0.52 |
Male | 39 (9.1) | 66 (9.3) | 1.0 |
Female | 15 (8.9) | 20 (5.9) | 0.19 |
Alcohol | 140 (23.5) | 256 (24.4) | 0.81 |
Male | 115 (26.9) | 196 (27.6) | 0.84 |
Female | 25 (14.9) | 60 (17.6) | 0.61 |
Others | 183 (30.8) | 315 (30.0) | 0.69 |
Male | 121 (28.3) | 201 (28.3) | 1.0 |
Female | 62 (36.9) | 114 (33.4) | 0.31 |
References
- Kam, A.W.; Chaudhry, S.G.; Gunasekaran, N.; White, A.J.; Vukasovic, M.; Fung, A.T. Fewer presentations to metropolitan emergency departments during the COVID-19 pandemic. Med. J. Aust. 2020, 213, 370–371. [Google Scholar] [CrossRef] [PubMed]
- Wagers, S. Domestic Violence Growing in Wake of Coronavirus Outbreak. The Conversation. Retrieved on 10 April 2020. Available online: https://theconversation.com/domestic-violence-growing-in-wake-of-coronavirus-outbreak-135598 (accessed on 24 April 2022).
- Kolla, B.P.; Oesterle, T.; Gold, M.; Southwick, F.; Rummans, T. Infectious diseases occurring in the context of substance use disorders: A concise review. J. Neurol. Sci. 2020, 411, 116719. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Yazdi, K.; Fuchs-Leitner, I.; Rosenleitner, J.; Gerstgrasser, N.W. Impact of the COVID-19 Pandemic on Patients with Alcohol Use Disorder and Associated Risk Factors for Relapse. Front. Psychiatry 2020, 11, 620612. [Google Scholar] [CrossRef] [PubMed]
- Avery, A.R.; Tsang, S.; Seto, E.Y.; Duncan, G.E. Stress, anxiety, and change in alcohol use during the COVID-19 pandemic: Findings among adult twin pairs. Front. Psychiatry 2020, 11, 571084. [Google Scholar] [CrossRef]
- Dubey, S.; Biswas, P.; Ghosh, R.; Chatterjee, S.; Dubey, M.J.; Chatterjee, S.; Lahiri, D.; Lavie, C.J. Psychosocial impact of COVID-19. Diabetes Metab. Syndr. 2020, 14, 779–788. [Google Scholar] [CrossRef]
- Jeffery, M.M.; D’Onofrio, G.; Paek, H.; Platts-Mills, T.F.; Soares, W.E.; Hoppe, J.A.; Genes, N.; Nath, B.; Melnick, E.R. Trends in emergency department visits and hospital admissions in health care systems in 5 states in the first months of the COVID-19 pandemic in the US. JAMA Intern Med. 2020, 180, 1328–1333. [Google Scholar] [CrossRef]
- Boursier, V.; Gioia, F.; Musetti, A.; Schimmenti, A. Facing Loneliness and Anxiety during the COVID-19 Isolation: The Role of Excessive Social Media Use in a Sample of Italian Adults. Front. Psychiatry 2020, 11, 586222. [Google Scholar] [CrossRef]
- Wei, Y.; Zhao, J.; Wong, I.C.; Wan, E.Y.; Taylor, D.M.; Blais, J.E.; Castle, D.J.; Knott, J.C.; Tse, M.L.; Chow, A.T.; et al. Relation of substance use disorders to mortality, accident and emergency department attendances, and hospital admissions: A 13-year population-based cohort study in Hong Kong. Drug Alcohol Depend. 2021, 229, 109119. [Google Scholar] [CrossRef]
- Krawczyk, N.; Eisenberg, M.; Schneider, K.E.; Richards, T.M.; Lyons, B.C.; Jackson, K.; Ferris, L.; Weiner, J.P.; Saloner, B. Predictors of overdose death among high-risk emergency department patients with substance-related encounters: A data linkage cohort study. Ann. Emerg. Med. 2020, 75, 1–12. [Google Scholar] [CrossRef][Green Version]
- Ibrahim, I.; Jacobs, I.G.; Webb, S.A.; Finn, J. Accuracy of International classification of diseases, 10th revision codes for identifying severe sepsis in patients admitted from the emergency department. Crit. Care Resusc. 2012, 14, 112–118. [Google Scholar]
- Bahorik, A.L.; Satre, D.D.; Kline-Simon, A.H.; Weisner, C.M.; Young-Wolff, K.C.; Campbell, C.I. Alcohol, marijuana, and opioid use disorders: 5-year patterns and characteristics of emergency department encounters. Subst. Abus. 2018, 39, 59–68. [Google Scholar] [CrossRef] [PubMed]
- Marel, C.; Mills, K.L.; Teesson, M. Substance use, mental disorders and COVID-19: A volatile mix. Curr. Opin. Psychiatry 2021, 34, 351–356. [Google Scholar] [CrossRef] [PubMed]
- 2019-nCoV National Incident Room Surveillance Team. 2019-nCoV Acute Respiratory Disease, Australia: Epidemiology Report 1 (Reporting Week 26 January–1 February 2020). Commun. Dis. Intell. 2020, 44, 32050080. [Google Scholar] [CrossRef]
- NSW Government. NSW Health Records and Information Privacy Act 2002 No 71. 2002. Available online: https://legislation.nsw.gov.au/view/html/inforce/current/act-2002-071 (accessed on 24 April 2022).
- McKenzie, S.; Lu, E. Privacy law: NCAT appeal panel taps off on the gold opal card case. Law Soc. NSW J. 2019, 59, 82–83. [Google Scholar]
- Englev, E.; Petersen, K.P. ICH-GCP Guideline: Quality assurance of clinical trials. Status and perspectives. Ugeskr. Laeger. 2003, 165, 1659–1662. [Google Scholar]
- Jacka, B.P.; Phipps, E.; Marshall, B.D. Drug use during a pandemic: Convergent risk of novel coronavirus and invasive bacterial and viral infections among people who use drugs. Int. J. Drug Policy 2020, 83, 102895. [Google Scholar] [CrossRef]
- Alexander, G.C.; Stoller, K.B.; Haffajee, R.L.; Saloner, B. An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. Ann. Intern. Med. 2020, 173, 57–58. [Google Scholar] [CrossRef][Green Version]
- Wang, Q.Q.; Kaelber, D.C.; Xu, R.; Volkow, N.D. COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States. Mol. Psychiatry 2021, 26, 30–39. [Google Scholar] [CrossRef]
- Coleman, M.; Taran, M.; Cuesta-Briand, B. Responding to rural adversity: A qualitative study of alcohol and other drug service users’ experiences of service response to COVID-19 in Western Australia’s Southwest. Australas. Psychiatry 2022, 30, 74–78. [Google Scholar] [CrossRef]
- Baillargeon, J.; Polychronopoulou, E.; Kuo, Y.F.; Raji, M.A. The Impact of Substance Use Disorder on COVID-19 Outcomes. Psychiatr. Serv. 2021, 72, 578–581. [Google Scholar] [CrossRef]
- Sutherland, K.; Chessman, J.; Zhao, J.; Sara, G.; Shetty, A.; Smith, S.; Went, A.; Dyson, S.; Levesque, J.F. Impact of COVID-19 on healthcare activity in NSW, Australia. Public Health Res. Pract. 2020, 30, 3042030. [Google Scholar] [CrossRef] [PubMed]
- Fuchs-Leitner, I.; Yazdi, K.; Gerstgrasser, N.W.; Rosenleitner, J. Developments in Drug Addiction during COVID-19—An Austrian Perspective Based on a Clinical Sample. Front. Psychiatry 2020, 11, 602033. [Google Scholar] [CrossRef] [PubMed]
- Farhoudian, A.; Baldacchino, A.; Clark, N.; Gerra, G.; Ekhtiari, H.; Dom, G.; Mokri, A.; Sadeghi, M.; Nematollahi, P.; Demasi, M.; et al. COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper. Basic Clin. Neurosci. 2020, 11, 133–150. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Marsden, J.; Darke, S.; Hall, W.; Hickman, M.; Holmes, J.; Humphreys, K.; Neale, J.; Tucker, J.; West, R. Mitigating and learning from the impact of COVID-19 infection on addictive disorders. Addiction 2020, 115, 1007–1010. [Google Scholar] [CrossRef][Green Version]
- Mackolil, J.; Mackolil, J. Addressing psychosocial problems associated with the COVID-19 lockdown. Asian J. Psychiatr. 2020, 51, 102156. [Google Scholar] [CrossRef]
- Wakeman, S.E.; Green, T.C.; Rich, J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat. Med. 2020, 26, 819–820. [Google Scholar] [CrossRef]
- Dunlop, A.; Lokuge, B.; Masters, D.; Sequeira, M.; Saul, P.; Dunlop, G.; Ryan, J.; Hall, M.; Ezard, N.; Haber, P.; et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct. J. 2020, 17, 26. [Google Scholar] [CrossRef]
- Velásquez García, H.A.; Wilton, J.; Smolina, K.; Chong, M.; Rasali, D.; Otterstatter, M.; Rose, C.; Prystajecky, N.; David, S.; Galanis, E.; et al. Mental Health and Substance Use Associated with Hospitalization among People with COVID-19: A Population-Based Cohort Study. Viruses 2021, 13, 2196. [Google Scholar] [CrossRef]
- Brotto, L.A.; Chankasingh, K.; Baaske, A.; Albert, A.; Booth, A.; Kaida, A.; Smith, L.W.; Racey, S.; Gottschlich, A.; Murray, M.C.M.; et al. The influence of sex, gender, age, and ethnicity on psychosocial factors and substance use throughout phases of the COVID-19 pandemic. PLoS ONE 2021, 16, e0259676. [Google Scholar] [CrossRef]
- Martinotti, G.; Alessi, M.C.; Di Natale, C.; Sociali, A.; Ceci, F.; Lucidi, L.; Picutti, E.; Di Carlo, F.; Corbo, M.; Vellante, F.; et al. Psychopathological Burden and Quality of Life in Substance Users during the COVID-19 Lockdown Period in Italy. Front. Psychiatry 2020, 11, 572245. [Google Scholar] [CrossRef]
- Thurber, K.A.; Barrett, E.M.; Agostino, J.; Chamberlain, C.; Ward, J.; Wade, V.; Belfrage, M.; Maddox, R.; Peiris, D.; Walker, J.; et al. Risk of severe illness from COVID-19 among Aboriginal and Torres Strait Islander adults: The construct of ‘vulnerable populations’ obscures the root causes of health inequities. Aust. N. Z. J. Public Health 2021, 45, 658–663. [Google Scholar] [CrossRef] [PubMed]
- COVID-19 National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 33 Fortnightly reporting period ending 17 January 2021. Commun. Dis. Intell. 2021, 45, 32552623. [Google Scholar] [CrossRef]
- Repici, A.; Pace, F.; Gabbiadini, R.; Colombo, M.; Hassan, C.; Dinelli, M.; ITALIAN GI-COVID19 Working Group. Endoscopy units and the coronavirus disease 2019 outbreak: A multicenter experience from Italy. Gastroenterology 2020, 159, 363–366.e3. [Google Scholar] [CrossRef] [PubMed]
- Gadsden, T.; Wilson, G.; Totterdell, J.; Willis, J.; Gupta, A.; Chong, A.; Clarke, A.; Winters, M.; Donahue, K.; Posenelli, S.; et al. Can a continuous quality improvement program create culturally safe emergency departments for Aboriginal people in Australia? A multiple baseline study. BMC Health Serv. Res. 2019, 19, 222. [Google Scholar] [CrossRef]
- Holland, C. Close the Gap 2018-A Ten Year Review: The Closing the Gap Strategy and Recommendations for Reset. 2018. Available online: https://humanrights.gov.au/our-work/aboriginal-and-torres-strait-islander-social-justice/publications/close-gap-10-year-review (accessed on 24 April 2022).
- Willis, J. Closing the gap-2020 marks a new era. Indep. Educ. 2020, 50, 16–17. [Google Scholar]
- Gwynne, K.; Jeffries, T.; Lincoln, M. Improving the efficacy of healthcare services for Aboriginal Australians. Aust. Health Rev. 2019, 43, 314–322. [Google Scholar] [CrossRef]
- Australian Indigenous HealthInfoNet. Overview of Aboriginal and Torres Strait Islander Health Status 2018. Perth: Australian Indigenous HealthInfoNet. 2019. Available online: https://healthinfonet.ecu.edu.au/healthinfonet/getContent.php?linkid=617557&title=Overview+of+Aboriginal+and+Torres+Strait+Islander+health+status+2018&contentid=36501_1 (accessed on 24 April 2022).
- Owen, S.; Carrington, K. Domestic violence (DV) service provision and the architecture of rural life: An Australian case study. J. Rural Stud. 2015, 39, 229–238. [Google Scholar] [CrossRef][Green Version]
- Ansari, S.; Boyle, A. Emergency department-based interventions for women suffering domestic abuse: A critical literature review. Eur. J. Emerg. Med. 2017, 24, 13–18. [Google Scholar] [CrossRef]
- Haregu, T.; Jorm, A.F.; Paradies, Y.; Leckning, B.; Young, J.T.; Armstrong, G. Discrimination experienced by Aboriginal and Torres Strait Islander males in Australia: Associations with suicidal thoughts and depressive symptoms. Aust. N. Z. J. Psychiatry 2021, in press. [Google Scholar] [CrossRef]
- Mellis, A.M.; Kelly, B.C.; Potenza, M.N.; Hulsey, J.N. Trust in a COVID-19 vaccine among people with substance use disorders. Drug Alcohol Depend. 2021, 220, 108519. [Google Scholar] [CrossRef]
- Dietze, P.M.; Hall, C.; Price, O.; Stewart, A.C.; Crawford, S.; Peacock, A.; Maher, L. COVID-19 vaccine acceptability among people in Australia who inject drugs: Implications for vaccine rollout. Drug Alcohol Rev. 2022, 41, 484–487. [Google Scholar] [CrossRef] [PubMed]
- Masson, C.L.; McCuistian, C.; Straus, E.; Elahi, S.; Chen, M.; Gruber, V.A.; Le, T.; Guydish, J. COVID-19 vaccine trust among clients in a sample of California residential substance use treatment programs. Drug Alcohol Depend. 2021, 225, 108812. [Google Scholar] [CrossRef] [PubMed]
- Blake, D.; Lyons, A. Opioid Substitution Treatment Planning in a Disaster Context: Perspectives from Emergency Management and Health Professionals in Aotearoa/New Zealand. Int. J. Environ. Res. Public Health 2016, 13, 1122. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Holland, K.M.; Jones, C.; Vivolo-Kantor, A.M.; Idaikkadar, N.; Zwald, M.; Hoots, B.; Yard, E.; D’Inverno, A.; Swedo, E.; Chen, M.S.; et al. Trends in US emergency department visits for mental health, overdose, and violence outcomes before and during the COVID-19 pandemic. JAMA Psychiatry 2021, 78, 372–379. [Google Scholar] [CrossRef]
- Hawk, K.F.; Vaca, F.E.; D’Onofrio, G. Reducing Fatal Opioid Overdose: Prevention, Treatment and Harm Reduction Strategies. Yale J. Biol. Med. 2015, 88, 235–245. [Google Scholar]
- Runyan, C.W.; Becker, A.; Brandspigel, S.; Barber, C.; Trudeau, A.; Novins, D. Lethal means counseling for parents of youth seeking emergency care for suicidality. West J. Emerg. Med. 2016, 17, 8–14. [Google Scholar] [CrossRef][Green Version]
- Stone, D.M.; Holland, K.M.; Bartholow, B.N.; Crosby, A.E.; Davis, S.P.; Wilkins, N. Preventing Suicide: A Technical Package of Policies, Programs, and Practices. Atlanta, GA: National Center for Injury Prevention and Control, Centers for Disease Control and Prevention. 2017. Available online: https://www.cdc.gov/violenceprevention/pdf/suicidetechnicalpackage.pdf (accessed on 24 April 2022).
- Centers for Disease Control and Prevention. Evidence-Based Strategies for Preventing Opioid Overdose: What’s Working in the United States. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. 2018. Available online: http://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf (accessed on 24 April 2022).
- Niolon, P.H.; Kearns, M.; Dills, J.; Rambo, K.; Irving, S.; Armstead, T.; Gilbert, L. Preventing Intimate Partner Violence across the Lifespan: A Technical Package of Programs, Policies, and Practices. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention: Atlanta, GA, USA. 2017. Available online: https://www.cdc.gov/violenceprevention/pdf/ipv-technicalpackages.pdf (accessed on 24 April 2022).
- Poorolajal, J.; Haghtalab, T.; Farhadi, M.; Darvishi, N. Substance use disorder and risk of suicidal ideation, suicide attempt and suicide death: A meta-analysis. J. Public Health 2016, 38, e282–e291. [Google Scholar] [CrossRef]
- Yasmin, F.; Najeeb, H.; Asghar, M.S.; Ullah, I.; Islam, S.M.S. Increased COVID-19 infection risk, COVID-19 vaccine inaccessibility, and unacceptability: Worrisome trio for patients with substance abuse disorders. J. Glob. Health 2021, 11, 03106. [Google Scholar] [CrossRef]
Demographic Details | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Male | 450 (1.1) | 745 (2.2) | <0.01 |
Indigenous | 46 (0.1) | 74 (0.2) | <0.01 |
Non-Indigenous | 404 (1.0) | 671 (1.9) | <0.01 |
Female | 215 (0.6) | 416 (1.2) | <0.01 |
Indigenous | 59 (0.2) | 90 (0.3) | 0.01 |
Non-Indigenous | 156 (0.4) | 326 (0.9) | <0.01 |
Category of Admission | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Drug | 19 (0.05) | 16 (0.05) | 0.99 |
Male | 2 (0.01) | 9 (0.03) | <0.05 |
Female | 17 (0.04) | 7 (0.02) | 0.10 |
Infection | 19 (0.05) | 40 (0.12) | <0.01 |
Male | 6 (0.02) | 22 (0.06) | <0.01 |
Female | 13 (0.03) | 18 (0.05) | 0.21 |
Local infection | 6 (0.02) | 19 (0.05) | <0.01 |
Male | 1 (0.003) | 9 (0.03) | <0.01 |
Female | 5 (0.01) | 10 (0.03) | 0.19 |
Gastrointestinal | 16 (0.04) | 16 (0.05) | 0.73 |
Male | 9 (0.02) | 7 (0.02) | 0.99 |
Female | 7 (0.02) | 9 (0.03) | 0.47 |
Trauma | 24 (0.06) | 43 (0.12) | <0.01 |
Male | 6 (0.02) | 4 (0.01) | 0.76 |
Female | 18 (0.05) | 39 (0.11) | <0.01 |
Alcohol | 4 (0.01) | 12 (0.03) | <0.05 |
Male | 4 (0.01) | 6 (0.02) | 0.53 |
Female | 0 (0.0) | 6 (0.02) | <0.05 |
Others | 23 (0.06) | 35 (0.10) | <0.05 |
Male | 19 (0.05) | 25 (0.07) | 0.23 |
Female | 4 (0.01) | 10 (0.03) | 0.10 |
Admission Category | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Drug | 48 (0.12) | 135 (0.39) | <0.01 |
Male | 27 (0.07) | 87 (0.25) | <0.01 |
Female | 21 (0.05) | 48 (0.14) | <0.01 |
Infection | 83 (0.21) | 117 (0.34) | <0.01 |
Male | 56 (0.14) | 67 (0.19) | 0.10 |
Female | 27 (0.07) | 50 (0.14) | <0.01 |
Local infection | 29 (0.07) | 61 (0.18) | <0.01 |
Male | 20 (0.05) | 46 (0.13) | <0.01 |
Female | 9 (0.02) | 15 (0.04) | 0.15 |
Gastrointestinal | 58 (0.15) | 80 (0.23) | <0.05 |
Male | 49 (0.12) | 46 (0.13) | 0.76 |
Female | 9 (0.02) | 34 (0.1) | <0.01 |
Trauma | 54 (0.14) | 86 (0.25) | <0.01 |
Male | 39 (0.10) | 66 (0.19) | <0.01 |
Female | 15 (0.04) | 20 (0.06) | 0.24 |
Alcohol | 140 (0.36) | 256 (0.74) | <0.01 |
Male | 115 (0.29) | 196 (0.57) | <0.01 |
Female | 25 (0.06) | 60 (0.17) | <0.01 |
Others | 183 (0.47) | 315 (0.91) | <0.01 |
Male | 121 (0.31) | 201 (0.58) | <0.01 |
Female | 62 (0.16) | 114 (0.33) | <0.01 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jefferies, M.; Rashid, H.; Graham, R.; Read, S.; Banik, G.R.; Lam, T.; Njiomegnie, G.F.; Eslam, M.; Zhao, X.; Ahmed, N.; Douglas, M.W.; George, J. COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. Vaccines 2022, 10, 889. https://doi.org/10.3390/vaccines10060889
Jefferies M, Rashid H, Graham R, Read S, Banik GR, Lam T, Njiomegnie GF, Eslam M, Zhao X, Ahmed N, Douglas MW, George J. COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. Vaccines. 2022; 10(6):889. https://doi.org/10.3390/vaccines10060889
Chicago/Turabian StyleJefferies, Meryem, Harunor Rashid, Robert Graham, Scott Read, Gouri R. Banik, Thao Lam, Gaitan F. Njiomegnie, Mohammed Eslam, Xiaojing Zhao, Nausheen Ahmed, Mark W. Douglas, and Jacob George. 2022. "COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out" Vaccines 10, no. 6: 889. https://doi.org/10.3390/vaccines10060889